- Home
- PNF vs QNCX Comparison
PNF vs QNCX Comparison
Compare PNF & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNF
- QNCX
- Stock Information
- Founded
- PNF 2001
- QNCX 2012
- Country
- PNF United States
- QNCX United States
- Employees
- PNF N/A
- QNCX N/A
- Industry
- PNF Finance Companies
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PNF Finance
- QNCX Health Care
- Exchange
- PNF Nasdaq
- QNCX Nasdaq
- Market Cap
- PNF 54.9M
- QNCX 47.7M
- IPO Year
- PNF N/A
- QNCX 2019
- Fundamental
- Price
- PNF N/A
- QNCX $1.66
- Analyst Decision
- PNF
- QNCX Strong Buy
- Analyst Count
- PNF 0
- QNCX 6
- Target Price
- PNF N/A
- QNCX $8.17
- AVG Volume (30 Days)
- PNF 29.1K
- QNCX 211.1K
- Earning Date
- PNF 01-01-0001
- QNCX 08-19-2025
- Dividend Yield
- PNF 5.17%
- QNCX N/A
- EPS Growth
- PNF N/A
- QNCX N/A
- EPS
- PNF N/A
- QNCX N/A
- Revenue
- PNF N/A
- QNCX N/A
- Revenue This Year
- PNF N/A
- QNCX N/A
- Revenue Next Year
- PNF N/A
- QNCX N/A
- P/E Ratio
- PNF N/A
- QNCX N/A
- Revenue Growth
- PNF N/A
- QNCX N/A
- 52 Week Low
- PNF $6.37
- QNCX $0.51
- 52 Week High
- PNF $9.06
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- PNF 10.55
- QNCX 49.52
- Support Level
- PNF $6.68
- QNCX $1.62
- Resistance Level
- PNF $7.64
- QNCX $1.75
- Average True Range (ATR)
- PNF 0.05
- QNCX 0.12
- MACD
- PNF -0.40
- QNCX -0.04
- Stochastic Oscillator
- PNF 0.00
- QNCX 16.22
About PNF PIMCO New York Municipal Income Fund
PIMCO New York Municipal Income Fund is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund's portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.